Can a simple blood test predict who responds to immunotherapy? Circulating L-arginine tracks checkpoint-inhibitor survival
Identification of super-exhausted T cells: a novel population predictive of response to immunotherapy
Background Most cancer patients treated with anti-PD1 or anti-PDL1 immune checkpoint blockers do not derive clinical benefit. There is therefore a crucial need to identify reliable predictive biomarkers of response. Beyond PD1, several immune checkpoints, including CTLA4, LAG3, TIM3 and TIGIT, are associated with a T cell exhausted phenotype and play an important role in […]
Does acetaminophen blunt cancer immunotherapy? Plasma evidence links paracetamol to worse checkpoint-inhibitor outcomes
How tertiary lymphoid structures predict pembrolizumab response in soft-tissue sarcoma — and why plasma cells matter
High regulatory T cells infiltrate within tertiary lymphoid structure restricts response to immune checkpoint blockers in sarcomas
Background The composition of the tumor microenvironment is a key determinant of effective anti-tumor immunity. In sarcomas, the presence of organized B and T cell aggregates, known as tertiary lymphoid structures, has recently been shown to predict response to immune checkpoint blockers. However, only a minority of patients derive clinical benefit from immune checkpoint […]
Development and characterization of a novel anti-PD1 resistant sarcoma mouse model
Soft tissue sarcoma (STS) is known to be resistant to cancer immunotherapy, including prototypical immune checkpoint inhibitors such as anti-PD1 antibodies. It is therefore crucial to develop innovative strategies aimed at improving current clinical benefit. To support this objective, well-characterized sarcoma preclinical models that mimic resistance to immunotherapy are needed. Starting from the anti-PD(L)1-sensitive MCA205 […]
Why IDO1 inhibitors fell short in cancer immunotherapy — and what comes next for tryptophan targeting
Can trabectedin plus durvalumab help platinum-resistant ovarian carcinoma and soft tissue sarcoma?
How mature TLSs identify solid tumor patients more likely to benefit from PD-1 blockade
How plasma LIF predicts immune-checkpoint blockade resistance and a TLS-poor tumor microenvironment
